Distinct molecular profile of IRF4-rearranged large B-cell lymphoma

Author:

Ramis-Zaldivar Joan Enric12ORCID,Gonzalez-Farré Blanca123ORCID,Balagué Olga3ORCID,Celis Verónica4,Nadeu Ferran12ORCID,Salmerón-Villalobos Julia1,Andrés Mara5,Martin-Guerrero Idoia67ORCID,Garrido-Pontnou Marta8ORCID,Gaafar Ayman9ORCID,Suñol Mariona10,Bárcena Carmen11,Garcia-Bragado Federico12,Andión Maitane13,Azorín Daniel14,Astigarraga Itziar7,Sagaseta de Ilurdoz Maria15ORCID,Sábado Constantino16ORCID,Gallego Soledad16ORCID,Verdú-Amorós Jaime17,Fernandez-Delgado Rafael17,Perez Vanesa18ORCID,Tapia Gustavo19,Mozos Anna20ORCID,Torrent Montserrat21,Solano-Páez Palma22,Rivas-Delgado Alfredo3,Dlouhy Ivan3,Clot Guillem12,Enjuanes Anna12,López-Guillermo Armando3,Galera Pallavi23,Oberley Matthew J.24ORCID,Maguire Alanna25ORCID,Ramsower Colleen25,Rimsza Lisa M.26,Quintanilla-Martinez Leticia27ORCID,Jaffe Elaine S.23ORCID,Campo Elías123ORCID,Salaverria Itziar12ORCID

Affiliation:

1. Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;

2. Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain;

3. Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain;

4. Pediatric Oncology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain;

5. Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain;

6. Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Leioa, Spain;

7. Pediatric Oncology Unit, Hospital Universitario Cruces Osakidetza, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain;

8. Pathology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain;

9. Pathology Department, Hospital Universitario Cruces Osakidetza, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain;

10. Pathology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain;

11. Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain;

12. Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain;

13. Pediatric Oncology Department and

14. Pathology Department, Hospital Universitario Infantil Niño Jesus, Madrid, Spain;

15. Pediatric Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain;

16. Pediatric Oncology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain;

17. Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain;

18. Pediatric Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain;

19. Pathology Department, Hospital Trias i Pujol, Badalona, Spain;

20. Pathology Department and

21. Pediatric Oncology Department, Hospital de Sant Pau i la Santa Creu, Barcelona, Spain;

22. Pediatric Oncology Department, Hospital Virgen del Rocio, Sevilla, Spain;

23. Laboratory of Pathology, National Institutes of Health, Bethesda, MD;

24. Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA;

25. Department of Research, Mayo Clinic, Scottsdale, AZ;

26. Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ; and

27. Institute of Pathology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany

Abstract

Abstract Pediatric large B-cell lymphomas (LBCLs) share morphological and phenotypic features with adult types but have better prognosis. The higher frequency of some subtypes such as LBCL with IRF4 rearrangement (LBCL-IRF4) in children suggests that some age-related biological differences may exist. To characterize the genetic and molecular heterogeneity of these tumors, we studied 31 diffuse LBCLs (DLBCLs), not otherwise specified (NOS); 20 LBCL-IRF4 cases; and 12 cases of high-grade B-cell lymphoma (HGBCL), NOS in patients ≤25 years using an integrated approach, including targeted gene sequencing, copy-number arrays, and gene expression profiling. Each subgroup displayed different molecular profiles. LBCL-IRF4 had frequent mutations in IRF4 and NF-κB pathway genes (CARD11, CD79B, and MYD88), losses of 17p13 and gains of chromosome 7, 11q12.3-q25, whereas DLBCL, NOS was predominantly of germinal center B-cell (GCB) subtype and carried gene mutations similar to the adult counterpart (eg, SOCS1 and KMT2D), gains of 2p16/REL, and losses of 19p13/CD70. A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma–related genes such as MYC, ID3, and DDX3X and homozygous deletions of 9p21/CDKN2A, whereas other cases were genetically closer to GCB DLBCL. Factors related to unfavorable outcome were age >18 years; activated B-cell (ABC) DLBCL profile, HGBCL, NOS, high genetic complexity, 1q21-q44 gains, 2p16/REL gains/amplifications, 19p13/CD70 homozygous deletions, and TP53 and MYC mutations. In conclusion, these findings further unravel the molecular heterogeneity of pediatric and young adult LBCL, improve the classification of this group of tumors, and provide new parameters for risk stratification.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3